Peptide-drug Conjugate Information
General Information of This Peptide-drug Conjugate (PDC)
| PDC ID |
PDC_00141
|
|||||
|---|---|---|---|---|---|---|
| PDC Name |
DOXoxmCPPamph
|
|||||
| PDC Status |
Investigative
|
|||||
| Indication |
In total 1 Indication(s)
Breast cancer
|
|||||
| Structure |
|
|||||
| Peptide Name |
oxmCPPamph
|
Peptide Info | ||||
| Drug Name |
Doxorubicin
|
Drug Info | ||||
| Therapeutic Target |
DNA topoisomerase 2-alpha (TOP2A)
|
Target Info | ||||
| Linker Name |
Disulfide bond
|
Linker Info | ||||
| Formula |
C144H205N27O41S2
|
|||||
| #Ro5 Violations (Lipinski): 4 | Molecular Weight | 3034.506 | ||||
| Lipid-water partition coefficient (xlogp) | -1.2835 | |||||
| Hydrogen Bond Donor Count (hbonddonor) | 25 | |||||
| Hydrogen Bond Acceptor Count (hbondacc) | 42 | |||||
| Rotatable Bond Count (rotbonds) | 69 | |||||
Full List of Activity Data of This Peptide-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Data of This PDC | [1] | ||||
| Indication | Breast cancer | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
19 μM
|
|||
| Description |
Doxorubicin binds with high affinity to DNA by intercalation, which leads to DNA damage and subsequent growth inhibition44,45. We performed MTT assays in order to determine the viability of the tumor cells and additionally to assess the proliferative potential of the cells after drug treatment. MCF-7 and HT-29 cells were incubated with doxorubicin and the peptide conjugates at various concentrations in the range of 0.1 and 50 μmfor 72 h (in a serum-containing medium), and the results were expressed as IC50-values (Table 1).
Click to Show/Hide
|
||||
| In Vitro Model | Colon cancer | HT29 cell | CVCL_A8EZ | ||
| Experiment 2 Reporting the Activity Data of This PDC | [1] | ||||
| Indication | Breast cancer | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
24.7 μM
|
|||
| Description |
Doxorubicin binds with high affinity to DNA by intercalation, which leads to DNA damage and subsequent growth inhibition44,45. We performed MTT assays in order to determine the viability of the tumor cells and additionally to assess the proliferative potential of the cells after drug treatment. MCF-7 and HT-29 cells were incubated with doxorubicin and the peptide conjugates at various concentrations in the range of 0.1 and 50 μmfor 72 h (in a serum-containing medium), and the results were expressed as IC50-values (Table 1).
Click to Show/Hide
|
||||
| In Vitro Model | Colon cancer | HT29 cell | CVCL_A8EZ | ||
References